Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced basal cell carcinoma.

Ten drugs were classified as low or no added therapeutic benefit compared with alternatives, accounting for $6.7 billion in ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The vast ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...